30 Participants Needed

Spinal Fusion Surgery with PEEK-OPTIMA™ HA Enhanced for Degenerative Disc Disease

KR
SO
Overseen BySheryl O'Farrell
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

The purpose of this trial is to collect clinical outcomes including radiographic and CT outcomes in patients who undergo spinal fusion using the Keos Lumbar Interbody Fusion Device.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, if you are on any drug treatment that affects bone metabolism, you may not be eligible to participate.

What data supports the effectiveness of the treatment Keos Lumbar Interbody Fusion Device, Keos Lumbar IBFD for degenerative disc disease?

Research shows that using PEEK (a type of plastic) rods and cages in spinal fusion surgeries can improve quality of life and reduce the need for additional surgeries. This suggests that the Keos Lumbar Interbody Fusion Device, which uses similar materials, may also be effective for treating degenerative disc disease.12345

Is the PEEK-OPTIMA™ HA Enhanced device safe for spinal fusion surgery?

Research shows that PEEK devices used in spinal fusion are generally safe, with no device degradation or harmful debris observed. Mild inflammation was noted, but PEEK systems are considered a safe alternative to traditional materials, reducing the need for further surgeries and preserving adjacent discs.12356

How is the Keos Lumbar Interbody Fusion Device treatment different from other treatments for degenerative disc disease?

The Keos Lumbar Interbody Fusion Device uses PEEK-OPTIMA™ HA Enhanced material, which is designed to improve bone fusion and reduce the risk of adjacent segment disease compared to traditional metal implants. This material is more flexible, potentially leading to better load distribution and less stress on surrounding areas, which may decrease the need for additional surgeries.13789

Research Team

LA

Louis A Marotti, M.D. PhD

Principal Investigator

Neurosurgical Associates of Lancaster

Eligibility Criteria

This trial is for adults over 18 with lower back issues like degenerative disc disease, spondylolisthesis, or retrolisthesis needing spinal fusion surgery. Participants must have tried non-surgical treatments for at least 6 months and be able to follow study procedures. Pregnant women, smokers, drug/alcohol abusers, those with certain diseases or bone metabolism-affecting drugs are excluded.

Inclusion Criteria

I have back pain caused by a disc problem.
I am of childbearing age and have a negative pregnancy test.
I have completed 6 months of non-surgical treatment.
See 5 more

Exclusion Criteria

I have rheumatoid arthritis, ankylosing spondylitis, or a weakened immune system.
I have been diagnosed with cancer.
I currently have an infection.
See 9 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo spinal fusion using the Keos Lumbar Interbody Fusion Device

Surgical procedure
1 visit (in-person)

Post-operative Follow-up

Participants are monitored for clinical outcomes, radiographic and CT outcomes

24 months
Multiple visits at 6 weeks, 3, 6, 12, and 24 months post-operatively

Treatment Details

Interventions

  • Keos Lumbar Interbody Fusion Device
Trial Overview The Keos Lumbar Interbody Fusion Device is being tested in patients requiring spinal fusion surgery. The study aims to assess the safety and performance of this device by monitoring clinical outcomes through radiographic and CT scans post-surgery.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: DeviceExperimental Treatment1 Intervention
All subjects who are entered into this trial will receive the Keos Lumbar Interbody Fusion Device.

Keos Lumbar Interbody Fusion Device is already approved in United States for the following indications:

🇺🇸
Approved in United States as Keos Lumbar IBFD for:
  • Spinal fusion procedure at one or two contiguous levels (L2-S1) in skeletally mature patients with degenerative disc disease (DDD)

Find a Clinic Near You

Who Is Running the Clinical Trial?

Invibio Ltd

Lead Sponsor

Trials
11
Recruited
380+

Keos LLC

Collaborator

Trials
1
Recruited
30+

Medical Metrics Diagnostics, Inc

Industry Sponsor

Trials
14
Recruited
1,800+

Technomics Research

Industry Sponsor

Trials
5
Recruited
880+

Viedoc Technologies

Collaborator

Trials
1
Recruited
30+

Findings from Research

In a study of 100 patients undergoing posterior lumbar interbody fusion (PLIF) with a non-threaded locking screw system and PEEK cages, the procedure successfully restored disc height and maintained fusion rates similar to traditional methods, with only a 2% rate of pseudarthrosis.
The non-threaded locking screw system resulted in significantly shorter operative times, less blood loss, and fewer dural tears compared to conventional bilateral cage systems, making it a safer and more efficient option for treating lumbar degenerative conditions.
100 consecutive cases of degenerative lumbar conditions using a non-threaded locking screw system with a 90-degree locking cap.McAfee, PC., Cunningham, BW., Tortolani, PJ., et al.[2020]
In a study involving eight adult sheep, implants coated with NanoMetalene (NM) showed significantly greater bone ingrowth and ongrowth compared to uncoated polyether ether ketone (PEEK) implants, indicating that NM enhances bone integration.
At both 4 and 8 weeks post-surgery, the NM-coated implants demonstrated new bone formation that tracked along the titanium layer, while PEEK implants exhibited nonreactive fibrous tissue, suggesting that NM may improve clinical outcomes for bone fusion devices.
The in vivo response to a novel Ti coating compared with polyether ether ketone: evaluation of the periphery and inner surfaces of an implant.Walsh, WR., Pelletier, MH., Christou, C., et al.[2023]
In a clinical study of 21 patients with lumbar degenerative disease, the use of PEEK rods in the Initial VEOS PEEK(®)-Optima system resulted in a low reoperation rate of 4.8% over an average follow-up of 2.5 years.
The PEEK rod system improved patients' quality of life by 16% and preserved the adjacent disc in over 70% of cases, suggesting it is a safe and effective alternative to traditional rigid instrumentation systems.
Flexible Stabilisation of the Degenerative Lumbar Spine Using PEEK Rods.Benezech, J., Garlenq, B., Larroque, G.[2020]

References

100 consecutive cases of degenerative lumbar conditions using a non-threaded locking screw system with a 90-degree locking cap. [2020]
The in vivo response to a novel Ti coating compared with polyether ether ketone: evaluation of the periphery and inner surfaces of an implant. [2023]
Flexible Stabilisation of the Degenerative Lumbar Spine Using PEEK Rods. [2020]
Comparison of the PEEK cage and an autologous cage made from the lumbar spinous process and laminae in posterior lumbar interbody fusion. [2022]
Polyetheretherketone (PEEK) Rods for Lumbar Fusion: A Systematic Review and Meta-Analysis. [2022]
Polyetheretherketone as a biomaterial for spinal applications. [2022]
Posterior lumbar fusion by peek rods in degenerative spine: preliminary report on 30 cases. [2022]
Do PEEK Rods for Posterior Instrumented Fusion in the Lumbar Spine Reduce the Risk of Adjacent Segment Disease? [2021]
Posterior spinal fusion using pedicle screws. [2022]